Chan, A T CA T CChanLee, V H FV H FLeeRUEY-LONG HONGAhn, M-JM-JAhnChong, W QW QChongKim, S-BS-BKimHo, G FG FHoCaguioa, P BP BCaguioaNgamphaiboon, NNNgamphaiboonHo, CCHoAziz, M A S AM A S AAzizNg, Q SQ SNgYen, C-JC-JYenSoparattanapaisarn, NNSoparattanapaisarnNgan, R K-CR K-CNganKho, S KS KKhoTiambeng, M L AM L ATiambengYun, TTYunSriuranpong, VVSriuranpongAlgazi, A PA PAlgaziCheng, AAChengMassarelli, EEMassarelliSwaby, R FR FSwabySaraf, SSSarafYuan, JJYuanSiu, L LL LSiu2023-07-142023-07-142023-0309237534https://scholars.lib.ntu.edu.tw/handle/123456789/633598Pembrolizumab previously demonstrated robust antitumor activity and manageable safety in a phase Ib study of patients with heavily pretreated, programmed death ligand 1 (PD-L1)-positive, recurrent or metastatic nasopharyngeal carcinoma (NPC). The phase III KEYNOTE-122 study was conducted to further evaluate pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent and/or metastatic NPC. Final analysis results are presented.enimmunotherapy; nasopharyngeal cancer; pembrolizumab; programmed death-1 (PD-1)[SDGs]SDG3journal article10.1016/j.annonc.2022.12.007365355662-s2.0-85147365199https://api.elsevier.com/content/abstract/scopus_id/85147365199